Recent news coverage is primarily market and macroeconomic related and does not pertain directly to Adaptin Bio's business or developments.

• Japanese stock market was notably higher on April 2, 2026 [N1].
• Soybeans closed with marginal weakness on April 2, 2026 [N2].
• Cotton closed with gains on April 2, 2026 [N3].
• Indian shares were set to drift lower as oil prices jumped after a prime time speech by former President Trump on April 2, 2026 [N4].
• FCA US reported Q1 sales up 4% on April 2, 2026 [N5].
• Additional support was anticipated for the Thai stock market on April 2, 2026 [N6].
• Higher open was expected for the Indonesia stock market on April 2, 2026 [N7].
• Toyota Motor North America reported March U.S. sales down 8.5% on April 2, 2026 [N8].

Adaptin Bio's innovative BRiTE platform addresses a critical unmet need in delivering therapeutics to the brain, a historically difficult target due to the blood brain barrier. The lead candidate APTN-101 targets EGFRvIII, a tumor-specific antigen expressed in glioblastoma and other cancers, potentially enabling precise immunotherapy with reduced off-target effects. Progress in FDA IND acceptances and IRB approvals for clinical trials demonstrates regulatory engagement and advancement. The company's capital-efficient outsourcing model and exclusive license from Duke University support focused development and potential expansion into other indications.

Adaptin Bio is pre-revenue and reports significant net losses and a working capital deficit, indicating liquidity risks and dependence on future capital raises. The clinical development of APTN-101 is at an early stage, with inherent risks of clinical trial failure, regulatory delays, and manufacturing challenges. The company's reliance on a single licensed technology platform and limited operational scale may constrain its ability to execute its strategy. Market and macroeconomic uncertainties, as well as competition in the immunotherapy space, add to execution risks.

Adaptin Bio's moat is based on its proprietary BRiTE platform technology licensed exclusively from Duke University, which enables targeted delivery of therapeutics across the blood brain barrier—a significant challenge in treating CNS diseases. The platform's focus on bispecific T-cell engagers targeting tumor-specific antigens like EGFRvIII offers a differentiated immunotherapy approach with potential advantages over existing treatments. The exclusive license agreement, ongoing clinical development, and intellectual property portfolio contribute to barriers to entry. However, the company faces typical biotech risks including clinical, regulatory, and funding challenges.

• Liquidity Risk: The company has a working capital deficit and limited cash reserves as of December 31, 2025, which may be insufficient to fund operations for the next twelve months without additional financing.
• Clinical Development Risk: APTN-101 and other product candidates are in early clinical stages, facing risks of trial delays, failure to demonstrate safety or efficacy, and regulatory hurdles.
• Dependence on Licensed Technology: Adaptin Bio's core technology is licensed exclusively from Duke University, with milestone and royalty obligations that may impact financials and operational flexibility.
• Operational and Execution Risk: The company operates with a small internal team and outsources most development and manufacturing activities, which may pose coordination and quality control challenges.
• Market and Macroeconomic Risks: General economic conditions, inflation, geopolitical events, and market volatility may affect the company's ability to raise capital and execute its business plan.

• Adaptin Bio, Inc. is a biopharmaceutical company focused on developing and commercializing products that enhance delivery of drugs and compounds to the brain and other tissues using novel technology licensed from Duke University in 2023 [S1].
• The company's proprietary platform technology is called BRiTE (Brain Bispecific T-cell Engager), designed to transport T cell targeting agents across the blood brain barrier (BBB) to treat brain cancers and other CNS disorders [S1].
• The lead product candidate is APTN-101, a bispecific T cell engager targeting EGFRvIII, a tumor-specific antigen expressed in glioblastoma, breast, and lung cancers [S1].
• APTN-101 has received FDA acceptance for an investigator-initiated IND for single-dose clinical trials in brain cancer in May 2023 and an amended IND for multi-dose trials accepted in October 2025 [S1].
• The company received Institutional Review Board (IRB) approval for a multi-dose clinical trial evaluating APTN-101 in glioblastoma multiforme (GBM) in March 2026 [S1].
• Adaptin Bio operates primarily through outsourcing, with a small employee base directing a large number of external vendors and consultants [S1].
• The company entered into an exclusive license agreement with Duke University for the BRiTE technology, including milestone payments and royalties, with Duke holding approximately 1.2% of the company's common stock on a fully diluted basis [S1].
• Financial snapshot as of December 31, 2025: cash and cash equivalents of $459,174; current assets of $619,159; current liabilities of $2,108,555; resulting in a current ratio of 0.29 and cash ratio of 0.22 [S1].
• Net loss for the year ended December 31, 2025 was $5,167,569 with basic and diluted EPS of -$0.66 [S1].
• The company has a working capital deficit of $1,489,396 and an accumulated deficit of $9,291,801 as of December 31, 2025 [S1].
• Adaptin Bio is an emerging growth company and smaller reporting company, electing to take advantage of certain reduced reporting requirements under the JOBS Act [S1].
• The company has not generated any revenue from product sales to date and is focused on research and development and administrative activities [S1].
• The company plans to advance APTN-101 development for glioblastoma and other cancers expressing EGFRvIII, including breast and lung cancers with or without brain metastases [S1].
• Adaptin Bio intends to design and advance other early-stage drug candidates for rare and unmet medical needs leveraging its delivery technology [S1].
• The company plans to outsource capital-intensive operations such as clinical development and manufacturing to specialist vendors to maintain capital efficiency [S1].
• The company faces liquidity risks as current cash and assets are insufficient to cover liabilities, and it plans to raise additional capital through equity or debt financings [S1].
• Glioblastoma is a highly malignant brain tumor with poor prognosis; current treatments have limited efficacy and significant side effects, highlighting the need for targeted immunotherapies like APTN-101 [S1].
• Bispecific T-cell engagers like APTN-101 offer advantages over CAR T-cell therapies, including scalable manufacturing and no need for lymphodepletion [S1].
• The company has not disclosed any material pending legal proceedings [S2].